APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angiotensin Receptor Blockers (ARBs)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Angiotensin Receptor Blockers (ARBs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchAngiotensin Receptor Blockers (ARBs) Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiotensin Receptor Blockers (ARBs) Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Angiotensin Receptor Blockers (ARBs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiotensin Receptor Blockers (ARBs) Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiotensin Receptor Blockers (ARBs) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Angiotensin Receptor Blockers (ARBs) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Angiotensin Receptor Blockers (ARBs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Angiotensin Receptor Blockers (ARBs) include Teva Pharmaceutical, Sanofi, Jhonson and Johnson, Novartis, Merck, Eli Lilly, Pfizer, GSK and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Angiotensin Receptor Blockers (ARBs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angiotensin Receptor Blockers (ARBs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angiotensin Receptor Blockers (ARBs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiotensin Receptor Blockers (ARBs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Angiotensin Receptor Blockers (ARBs) Segment by Company

Teva Pharmaceutical

Sanofi

Jhonson and Johnson

Novartis

Merck

Eli Lilly

Pfizer

GSK

Bayer

Bristol-Myers Squibb

Astra Zeneca

Angiotensin Receptor Blockers (ARBs) Segment by Type

Valsartan

Telmisartan

Losartan

Irbesartan

Olmesartan

Azilsartan

Angiotensin Receptor Blockers (ARBs) Segment by Application

Cardiovascular Diseases

Kidney Diseases

Hypertension

Other

Angiotensin Receptor Blockers (ARBs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiotensin Receptor Blockers (ARBs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiotensin Receptor Blockers (ARBs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiotensin Receptor Blockers (ARBs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Angiotensin Receptor Blockers (ARBs) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Angiotensin Receptor Blockers (ARBs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Angiotensin Receptor Blockers (ARBs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Angiotensin Receptor Blockers (ARBs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Angiotensin Receptor Blockers (ARBs) Industry Trends Table 2. Angiotensin Receptor Blockers (ARBs) Industry Drivers Table 3. Angiotensin Receptor Blockers (ARBs) Industry Opportunities and Challenges Table 4. Angiotensin Receptor Blockers (ARBs) Industry Restraints Table 5. Global Angiotensin Receptor Blockers (ARBs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Angiotensin Receptor Blockers (ARBs) Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Manufacturers Table 9. Global Angiotensin Receptor Blockers (ARBs) Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Angiotensin Receptor Blockers (ARBs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Angiotensin Receptor Blockers (ARBs) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Angiotensin Receptor Blockers (ARBs) Manufacturers, Product Type & Application Table 13. Global Angiotensin Receptor Blockers (ARBs) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Angiotensin Receptor Blockers (ARBs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Valsartan Table 17. Major Manufacturers of Telmisartan Table 18. Major Manufacturers of Losartan Table 19. Major Manufacturers of Irbesartan Table 20. Major Manufacturers of Olmesartan Table 21. Major Manufacturers of Azilsartan Table 22. Global Angiotensin Receptor Blockers (ARBs) Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 23. Global Angiotensin Receptor Blockers (ARBs) Sales by Type (2021-2026) & (k tons) Table 24. Global Angiotensin Receptor Blockers (ARBs) Sales by Type (2027-2032) & (k tons) Table 25. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Type (2021-2026) Table 26. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Type (2027-2032) Table 27. Global Angiotensin Receptor Blockers (ARBs) Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 28. Global Angiotensin Receptor Blockers (ARBs) Revenue by Type (2021-2026) & (k tons) Table 29. Global Angiotensin Receptor Blockers (ARBs) Revenue by Type (2027-2032) & (k tons) Table 30. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Type (2021-2026) Table 31. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Cardiovascular Diseases Table 33. Major Manufacturers of Kidney Diseases Table 34. Major Manufacturers of Hypertension Table 35. Major Manufacturers of Other Table 36. Global Angiotensin Receptor Blockers (ARBs) Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 37. Global Angiotensin Receptor Blockers (ARBs) Sales by Application (2021-2026) & (k tons) Table 38. Global Angiotensin Receptor Blockers (ARBs) Sales by Application (2027-2032) & (k tons) Table 39. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Application (2021-2026) Table 40. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Application (2027-2032) Table 41. Global Angiotensin Receptor Blockers (ARBs) Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 42. Global Angiotensin Receptor Blockers (ARBs) Revenue by Application (2021-2026) & (k tons) Table 43. Global Angiotensin Receptor Blockers (ARBs) Revenue by Application (2027-2032) & (k tons) Table 44. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Application (2021-2026) Table 45. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Application (2027-2032) Table 46. Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 47. Global Angiotensin Receptor Blockers (ARBs) Sales by Region (2021-2026) & (k tons) Table 48. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Region (2021-2026) Table 49. Global Angiotensin Receptor Blockers (ARBs) Sales Forecasted by Region (2027-2032) & (k tons) Table 50. Global Angiotensin Receptor Blockers (ARBs) Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Angiotensin Receptor Blockers (ARBs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 52. North America Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026) & (k tons) Table 53. North America Angiotensin Receptor Blockers (ARBs) Sales by Country (2027-2032) & (k tons) Table 54. Europe Angiotensin Receptor Blockers (ARBs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 55. Europe Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026) & (k tons) Table 56. Europe Angiotensin Receptor Blockers (ARBs) Sales by Country (2027-2032) & (k tons) Table 57. Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 58. Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026) & (k tons) Table 59. Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales by Country (2027-2032) & (k tons) Table 60. South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 61. South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2026) & (k tons) Table 62. South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales by Country (2027-2032) & (k tons) Table 63. Global Angiotensin Receptor Blockers (ARBs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Angiotensin Receptor Blockers (ARBs) Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Angiotensin Receptor Blockers (ARBs) Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Region (2021-2026) Table 67. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Region (2027-2032) Table 68. Teva Pharmaceutical Company Information Table 69. Teva Pharmaceutical Business Overview Table 70. Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 72. Teva Pharmaceutical Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sanofi Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 77. Sanofi Recent Development Table 78. Jhonson and Johnson Company Information Table 79. Jhonson and Johnson Business Overview Table 80. Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 82. Jhonson and Johnson Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 87. Novartis Recent Development Table 88. Merck Company Information Table 89. Merck Business Overview Table 90. Merck Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Merck Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 92. Merck Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Pfizer Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 102. Pfizer Recent Development Table 103. GSK Company Information Table 104. GSK Business Overview Table 105. GSK Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. GSK Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 107. GSK Recent Development Table 108. Bayer Company Information Table 109. Bayer Business Overview Table 110. Bayer Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Bayer Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 112. Bayer Recent Development Table 113. Bristol-Myers Squibb Company Information Table 114. Bristol-Myers Squibb Business Overview Table 115. Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 117. Bristol-Myers Squibb Recent Development Table 118. Astra Zeneca Company Information Table 119. Astra Zeneca Business Overview Table 120. Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Portfolio Table 122. Astra Zeneca Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Angiotensin Receptor Blockers (ARBs) Distributors List Table 126. Angiotensin Receptor Blockers (ARBs) Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Angiotensin Receptor Blockers (ARBs) Product Image Figure 2. Global Angiotensin Receptor Blockers (ARBs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiotensin Receptor Blockers (ARBs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Angiotensin Receptor Blockers (ARBs) Sales (2021-2032) & (k tons) Figure 5. Global Angiotensin Receptor Blockers (ARBs) Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Angiotensin Receptor Blockers (ARBs) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Valsartan Image Figure 9. Telmisartan Image Figure 10. Losartan Image Figure 11. Irbesartan Image Figure 12. Olmesartan Image Figure 13. Azilsartan Image Figure 14. Global Angiotensin Receptor Blockers (ARBs) Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 15. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Type (2021-2032) Figure 17. Global Angiotensin Receptor Blockers (ARBs) Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 18. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Type (2021-2032) Figure 20. Cardiovascular Diseases Image Figure 21. Kidney Diseases Image Figure 22. Hypertension Image Figure 23. Other Image Figure 24. Global Angiotensin Receptor Blockers (ARBs) Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 25. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Application (2021-2032) Figure 27. Global Angiotensin Receptor Blockers (ARBs) Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 28. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Application (2021-2032) Figure 30. North America Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 31. North America Angiotensin Receptor Blockers (ARBs) Sales Market Share by Country (2021-2032) Figure 32. U.S. Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 33. Canada Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 34. Mexico Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 35. Europe Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 36. Europe Angiotensin Receptor Blockers (ARBs) Sales Market Share by Country (2021-2032) Figure 37. Germany Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 38. France Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 39. U.K. Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 40. Italy Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 41. Netherlands Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 42. Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 43. Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales Market Share by Country (2021-2032) Figure 44. China Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 45. Japan Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 46. South Korea Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 47. Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 48. India Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 49. Australia Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 50. South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 51. South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales Market Share by Country (2021-2032) Figure 52. Brazil Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 53. South Africa Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 54. Saudi Arabia Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 55. Turkey Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 56. Argentina Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 57. UAE Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 58. Egypt Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 59. Chile Angiotensin Receptor Blockers (ARBs) Sales and Growth Rate (2021-2032) & (k tons) Figure 60. Global Angiotensin Receptor Blockers (ARBs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Angiotensin Receptor Blockers (ARBs) Revenue (2021-2032) & (US$ Million) Figure 63. North America Angiotensin Receptor Blockers (ARBs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Angiotensin Receptor Blockers (ARBs) Revenue (2021-2032) & (US$ Million) Figure 65. Europe Angiotensin Receptor Blockers (ARBs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Angiotensin Receptor Blockers (ARBs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Angiotensin Receptor Blockers (ARBs) Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Angiotensin Receptor Blockers (ARBs) Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Valsartan
  • Telmisartan
  • Losartan
  • Irbesartan
  • Olmesartan
  • Azilsartan
Applications
  • Cardiovascular Diseases
  • Kidney Diseases
  • Hypertension
  • Other
Companies covered
  • Teva Pharmaceutical
  • Sanofi
  • Jhonson and Johnson
  • Novartis
  • Merck
  • Eli Lilly
  • Pfizer
  • GSK
  • Bayer
  • Bristol-Myers Squibb
  • Astra Zeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Angiotensin Receptor Blockers (ARBs) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Angiotensin Receptor Blockers (ARBs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Angiotensin Receptor Blockers (ARBs) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Angiotensin Receptor Blockers (ARBs) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Angiotensin Receptor Blockers (ARBs) Market Dynamics
  1. 2.1 Angiotensin Receptor Blockers (ARBs) Industry Trends
  2. 2.2 Angiotensin Receptor Blockers (ARBs) Industry Drivers
  3. 2.3 Angiotensin Receptor Blockers (ARBs) Industry Opportunities and Challenges
  4. 2.4 Angiotensin Receptor Blockers (ARBs) Industry Restraints
3 Angiotensin Receptor Blockers (ARBs) Market by Manufacturers
  1. 3.1 Global Angiotensin Receptor Blockers (ARBs) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Angiotensin Receptor Blockers (ARBs) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Angiotensin Receptor Blockers (ARBs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Angiotensin Receptor Blockers (ARBs) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Angiotensin Receptor Blockers (ARBs) Manufacturers, Product Type & Application
  7. 3.7 Global Angiotensin Receptor Blockers (ARBs) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Angiotensin Receptor Blockers (ARBs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Angiotensin Receptor Blockers (ARBs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Angiotensin Receptor Blockers (ARBs) Tier 1, Tier 2, and Tier 3
4 Angiotensin Receptor Blockers (ARBs) Market by Type
  1. 4.1 Angiotensin Receptor Blockers (ARBs) Type Introduction
  2. 4.1.1 Valsartan
  3. 4.1.2 Telmisartan
  4. 4.1.3 Losartan
  5. 4.1.4 Irbesartan
  6. 4.1.5 Olmesartan
  7. 4.1.6 Azilsartan
  8. 4.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Type
  9. 4.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Type (2021-2032)
  11. 4.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Type (2021-2032)
  12. 4.3 Global Angiotensin Receptor Blockers (ARBs) Revenue by Type
  13. 4.3.1 Global Angiotensin Receptor Blockers (ARBs) Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Type (2021-2032)
  15. 4.3.3 Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Type (2021-2032)
5 Angiotensin Receptor Blockers (ARBs) Market by Application
  1. 5.1 Angiotensin Receptor Blockers (ARBs) Application Introduction
  2. 5.1.1 Cardiovascular Diseases
  3. 5.1.2 Kidney Diseases
  4. 5.1.3 Hypertension
  5. 5.1.4 Other
  6. 5.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Application
  7. 5.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Application (2021-2032)
  9. 5.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Market Share by Application (2021-2032)
  10. 5.3 Global Angiotensin Receptor Blockers (ARBs) Revenue by Application
  11. 5.3.1 Global Angiotensin Receptor Blockers (ARBs) Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Application (2021-2032)
  13. 5.3.3 Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Application (2021-2032)
6 Global Angiotensin Receptor Blockers (ARBs) Sales by Region
  1. 6.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angiotensin Receptor Blockers (ARBs) Sales by Region (2021-2032)
  3. 6.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales by Region (2021-2026)
  4. 6.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Angiotensin Receptor Blockers (ARBs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Angiotensin Receptor Blockers (ARBs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Angiotensin Receptor Blockers (ARBs) Revenue by Region
  1. 7.1 Global Angiotensin Receptor Blockers (ARBs) Revenue by Region
  2. 7.1.1 Global Angiotensin Receptor Blockers (ARBs) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Region (2021-2026)
  4. 7.1.3 Global Angiotensin Receptor Blockers (ARBs) Revenue by Region (2027-2032)
  5. 7.1.4 Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Angiotensin Receptor Blockers (ARBs) Revenue (2021-2032)
  8. 7.2.2 North America Angiotensin Receptor Blockers (ARBs) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Angiotensin Receptor Blockers (ARBs) Revenue (2021-2032)
  11. 7.3.2 Europe Angiotensin Receptor Blockers (ARBs) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Angiotensin Receptor Blockers (ARBs) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Angiotensin Receptor Blockers (ARBs) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Angiotensin Receptor Blockers (ARBs) Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Jhonson and Johnson
  14. 8.3.1 Jhonson and Johnson Company Information
  15. 8.3.2 Jhonson and Johnson Business Overview
  16. 8.3.3 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Portfolio
  18. 8.3.5 Jhonson and Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Angiotensin Receptor Blockers (ARBs) Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Angiotensin Receptor Blockers (ARBs) Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Angiotensin Receptor Blockers (ARBs) Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK Angiotensin Receptor Blockers (ARBs) Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Bayer
  50. 8.9.1 Bayer Company Information
  51. 8.9.2 Bayer Business Overview
  52. 8.9.3 Bayer Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bayer Angiotensin Receptor Blockers (ARBs) Product Portfolio
  54. 8.9.5 Bayer Recent Developments
  55. 8.10 Bristol-Myers Squibb
  56. 8.10.1 Bristol-Myers Squibb Company Information
  57. 8.10.2 Bristol-Myers Squibb Business Overview
  58. 8.10.3 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Recent Developments
  61. 8.11 Astra Zeneca
  62. 8.11.1 Astra Zeneca Company Information
  63. 8.11.2 Astra Zeneca Business Overview
  64. 8.11.3 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Portfolio
  66. 8.11.5 Astra Zeneca Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Angiotensin Receptor Blockers (ARBs) Value Chain Analysis
  2. 9.1.1 Angiotensin Receptor Blockers (ARBs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Angiotensin Receptor Blockers (ARBs) Production Mode & Process
  6. 9.2 Angiotensin Receptor Blockers (ARBs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Angiotensin Receptor Blockers (ARBs) Distributors
  9. 9.2.3 Angiotensin Receptor Blockers (ARBs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst